US Patent 9,248,199: Scope, Claims, and Patent Landscape for HbS Oxygen-Affinity/Occlusion Therapy Using a Benzaldehyde Pyrazolylpyridine Ether
United States Patent 9,248,199 covers a method of increasing the oxygen affinity of sickle hemoglobin (HbS) and inhibiting HbS sickling in vivo via administration of a single named small molecule (or a salt) described as: 2-(((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)oxy)methyl)-6-hydroxybenzaldehyde, including its salts. The operative scope is defined by formation of a 1:1 HbS adduct in vivo, where the adduct increases oxygen affinity and inhibits sickling.
What is the invention’s functional “center of gravity”?
The claim language makes HbS binding and adduct stoichiometry in vivo the pivot:
- Target: sickle hemoglobin (HbS)
- Mechanism: the administered compound binds to HbS to form a 1:1 adduct in vivo
- Functional outcomes (claim-dependent):
- Claim 1: adduct increases oxygen affinity
- Claim 2: adduct inhibits sickling
This makes the enforceable boundary less about a broad “oxygen affinity increase” concept and more about doing it with this specific benzaldehyde ether scaffold under conditions that produce the 1:1 HbS adduct.
How broad is the claim scope by compound definition?
Core active ingredient
Both claims are limited to administration of:
- 2-(((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)oxy)methyl)-6-hydroxybenzaldehyde
- or a salt thereof
There is no claim text that expands to:
- other aldehydes,
- other pyrazolylpyridines,
- other substitution patterns on the 6-hydroxybenzaldehyde ring,
- analogs lacking the exact linker/ether arrangement,
- prodrugs, polymorphs, solvates, or formulation-only variants (unless they still administer the same compound or its salt as claimed).
Structural lock-in risk for design-around
Because the active is recited in full chemical name form (not as a Markush group), the claim’s “chemical scope” is tightly anchored. A competitor that substitutes any part of the core structure (pyrazole substitution, pyridine substitution pattern, ether linkage, benzaldehyde hydroxy position, or aldehyde itself) risks falling outside the literal wording unless it still uses the same compound/salt.
What does “a sufficient amount” cover, and how does that affect enforceability?
“A sufficient amount” is a dose-intent trigger, not a specific mg/kg number. In practice, this:
- preserves flexibility for the patentee to argue dose ranges that still achieve HbS binding and the claimed in vivo adduct formation;
- creates litigation leverage for claim construction arguments around what counts as “sufficient” to:
- achieve 1:1 adduct formation in vivo; and
- achieve the downstream oxygen-affinity increase (Claim 1) or anti-sickling effect (Claim 2).
Still, because the claims do not quantify dose, there is no explicit numeric ceiling or floor that can be used to carve out non-infringing dosing.
How broad is the patient population?
Both claims cover:
- “a patient in need thereof”
- no restriction by age, genotype beyond HbS being the sickle hemoglobin, severity, or comedications
That language is broad. It does not limit to adults, pediatrics, transfusion-dependent patients, or particular clinical phenotypes.
Is “in vivo 1:1 adduct” a hard boundary or a scientific description?
It is both a mechanistic requirement and a constraint on infringement theory. The claims require that administration be such that the compound:
- binds to HbS
- forms a 1:1 adduct in vivo
This does two things:
- It limits direct infringement to situations where the claimed binding stoichiometry occurs in vivo.
- It creates potential evidentiary focus: the patentee will typically rely on biochemical/biophysical characterization demonstrating 1:1 complex formation under physiological conditions, or surrogate assays that correlate with 1:1 adduct formation.
From a competitor perspective, design-around options that change stoichiometry (for example, compounds binding HbS at different stoichiometries or forming mixtures of species) could be argued as outside “1:1 adduct” even if oxygen affinity changes.
What is the scope distinction between Claim 1 and Claim 2?
Claim 1 (oxygen affinity)
- Requires: adduct that “increases the oxygen affinity of said HbS”
- Key outcome: oxygen affinity increase is the claimed effect
Claim 2 (anti-sickling)
- Requires: adduct that “thereby inhibiting sickling of HbS”
- Key outcome: sickling inhibition is the claimed effect
Both depend on the same adduct formation requirement. The difference is the endpoint. That matters because a compound could, in theory, form the same adduct but show different physiologic effects across assay conditions (Claim 1) or clinical endpoints (Claim 2). The claims still require the relevant functional outcome under “in vivo” conditions.
What exactly are the independent claim elements?
Claim 1 element-by-element
- Administering to a patient in need thereof
- A sufficient amount of:
- 2-(((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)oxy)methyl)-6-hydroxybenzaldehyde or a salt
- Such that the compound “binds to HbS”
- Such that the compound forms “a 1:1 adduct in vivo”
- Such that the adduct “increases the oxygen affinity of said HbS”
Claim 2 element-by-element
- Administering to a patient in need thereof
- A composition comprising the same compound or a salt
- Such that it binds to HbS
- Such that it forms a “1:1 adduct in vivo”
- Such that the adduct “thereby inhibiting sickling of HbS”
How does claim wording affect “product” versus “method” infringement?
These are method-of-treatment claims. They capture acts of administration, not just possession or manufacturing of the compound.
A generic or formulation company that sells the compound for research use would not automatically infringe. A company promoting or delivering it into patients “in need thereof” could be accused of direct infringement if the other elements are met, particularly in vivo 1:1 adduct formation and the functional endpoint.
How does this patent fit into the broader HbS oxygen-modifier landscape?
The claims track a common mechanistic theme in sickle cell pharmacology: small molecules that shift HbS oxygen affinity or otherwise stabilize non-sickling hemoglobin states. However, this patent’s enforceable hook is specific compound identity plus a 1:1 HbS adduct.
What are the most relevant competitor claim categories around this patent?
1) Direct analogs that match the exact compound identity
- If a competitor sells the same compound/salt and a prescriber administers it to patients such that in vivo 1:1 HbS adduct forms and oxygen affinity/sickling effects occur, infringement risk is highest.
2) Structural analogs that retain the “1:1 adduct” behavior
- Even if the chemical name differs, a patentee may argue equivalents depending on claim construction and prosecution history, but literal infringement requires the claimed compound or salts.
3) Compounds that change oxygen affinity without forming a 1:1 HbS adduct
- If a compound increases oxygen affinity via different binding modes (or yields different stoichiometries), it may fall outside the “1:1 adduct in vivo” requirement.
4) Compounds that inhibit sickling via different mechanisms
- Crizanlizumab (anti-P selectin), hydroxyurea (HbF induction), L-glutamine, voxelotor (direct HbS oxygen affinity modulation) and others operate through distinct targets or modes. This patent’s claim hook is HbS adduct stoichiometry with a specified small molecule class.
Which existing drug classes most likely overlap on the mechanism axis?
Even without mapping every related patent family in this dataset, the functional outcomes align to at least two broad therapeutic buckets:
- Oxygen affinity modifiers: agents that increase oxygen affinity to reduce HbS polymerization/sickling propensity.
- Anti-sickling agents via other pathways: agents that reduce polymerization indirectly or reduce vascular adhesion.
US 9,248,199 is best categorized with oxygen affinity modifiers, but it is narrower because it specifies a particular chemical structure and demands 1:1 HbS adduct formation.
What does “patent landscape” mean here, operationally?
For investment and R&D planning, the landscape question breaks into three enforceability vectors:
- Compound identity lock-in
- If the candidate molecule is the same compound or a salt, 9,248,199 is directly relevant.
- Mechanistic equivalence via adduct stoichiometry
- If a candidate forms a 1:1 HbS adduct in vivo and achieves the same endpoints, it is closer on function, even if not identical chemical structure.
- Endpoint selection for freedom-to-operate
- If a candidate pursues sickling inhibition without claiming oxygen affinity increase (or vice versa), this may still collide because both claims require the same adduct formation and cover different outcomes.
Patent-scope implications for pipeline and licensing
Likely strongest enforcement theory
- Administration of the claimed compound/salt to a patient such that it forms a 1:1 HbS adduct in vivo and produces the claimed oxygen affinity or anti-sickling effect.
Likely design-around pressure points
- Replace the compound scaffold (literal avoidance).
- Engineer alternative binding behavior that does not form the required 1:1 adduct.
- Avoid the claimed endpoint chain (harder in practice because oxygen affinity and sickling inhibition correlate clinically, but claims still require specific functional outcomes).
Claim-by-claim risk map for R&D and FTO (based on the provided claim text)
Claim 1 risk drivers
- Using the exact compound/salt
- Showing in vivo 1:1 HbS adduct formation
- Achieving increased oxygen affinity in vivo
Claim 2 risk drivers
- Using the exact compound/salt
- Showing in vivo 1:1 HbS adduct formation
- Demonstrating inhibition of HbS sickling
Scenario mapping (how a court may read the claims)
| Technical fact pattern |
Claim 1 |
Claim 2 |
| Exact compound/salt + 1:1 adduct + higher HbS oxygen affinity |
High infringement risk |
Moderate-to-low (depending on sickling inhibition evidence) |
| Exact compound/salt + 1:1 adduct + inhibits sickling |
Lower risk for Claim 1 only if oxygen affinity endpoint is not met; still litigable |
High infringement risk |
| Analog compound (not the same chemical name) but forms a 1:1 adduct |
Depends on literal scope; likely lower literal risk |
Depends on literal scope; likely lower literal risk |
This map assumes the claim is construed as written, with literal limitation to the specified compound/salt.
What is missing for a full US “patent landscape” map?
A complete patent landscape requires the patent family members, priority chain, related continuations, prosecution history, and citing/cited documents in the US system. Those data are not present in the record provided. The analysis above therefore limits itself to scope and enforceability logic embedded in the claim text.
(Per instruction constraints, no additional data requests or speculation are included.)
Key Takeaways
- US 9,248,199 covers in vivo methods using 2-(((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)oxy)methyl)-6-hydroxybenzaldehyde (or salts).
- The claims require HbS binding and formation of a 1:1 HbS adduct in vivo.
- Claim 1 requires that the adduct increases HbS oxygen affinity; Claim 2 requires that it inhibits HbS sickling.
- The compound definition is structurally tight (full chemical name), so design-arounds most plausibly hinge on avoiding literal identity or avoiding the 1:1 adduct behavior.
- Landscape relevance is highest for candidates that match the same molecule/salt and reproduce the 1:1 adduct + oxygen affinity/anti-sickling outcomes.
FAQs
1) Do the claims cover manufacturing the compound, or only administering it?
They are method-of-treatment claims, so the infringement trigger is tied to administering the compound to patients “in need thereof,” under conditions producing the claimed in vivo effects.
2) Is the “1:1 adduct in vivo” requirement common to both claims?
Yes. Both Claim 1 and Claim 2 require that the administered compound forms a 1:1 adduct in vivo with HbS.
3) Can a competitor avoid liability by dosing differently?
The claims use “a sufficient amount,” without numeric dose limits. Dose strategy alone is unlikely to avoid infringement if the other claim elements, including in vivo adduct formation and the functional endpoint, are met.
4) Does Claim 2 also require increased oxygen affinity?
No. Claim 2 requires inhibiting sickling via the in vivo 1:1 HbS adduct. It does not explicitly recite oxygen affinity as an endpoint.
5) What is the most direct design-around based on the claim text?
Avoid literal use of the recited compound/salt and/or avoid the claimed in vivo 1:1 HbS adduct formation behavior.
References
- US Patent 9,248,199 (claims as provided).
